Trial Search Results

Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss

The objective is to assess the feasibility, safety and efficacy of up to 3 intratympanic administrations of OTO-104 in the study drug ear compared to no treatment in the control ear in subjects aged 6 months to 21 years, inclusive, receiving cisplatin chemotherapy regimens to treat cancer.

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting